- Home
- ACRE vs CGEN Comparison
ACRE vs CGEN Comparison
Compare ACRE & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACRE | CGEN |
|---|---|---|
| Founded | 2011 | 1993 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 254.1M | 220.7M |
| IPO Year | 2012 | 2000 |
Fundamental Metrics
Financial Performance| Metric | ACRE | CGEN |
|---|---|---|
| Price | $4.85 | $2.16 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | ★ $5.33 | $4.00 |
| AVG Volume (30 Days) | 580.8K | ★ 597.4K |
| Earning Date | 02-11-2026 | 03-03-2026 |
| Dividend Yield | ★ 12.15% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $87,777,000.00 | $6,903,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $164.92 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 122.65 | N/A |
| 52 Week Low | $3.35 | $1.13 |
| 52 Week High | $6.10 | $2.66 |
Technical Indicators
Market Signals| Indicator | ACRE | CGEN |
|---|---|---|
| Relative Strength Index (RSI) | 43.96 | 66.02 |
| Support Level | $4.81 | $2.04 |
| Resistance Level | $5.16 | $2.38 |
| Average True Range (ATR) | 0.14 | 0.15 |
| MACD | 0.00 | 0.05 |
| Stochastic Oscillator | 47.01 | 73.64 |
Price Performance
Historical ComparisonAbout ACRE Ares Commercial Real Estate Corporation
Ares Commercial Real Estate Corp is a specialty finance company and a Real Estate Investment Trust providing commercial real estate loans and related investments. It operates in one segment namely originating and managing a diversified portfolio of CRE debt-related investments. The group recognizes its revenues through the interest income it receives from loans.
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.